The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials.
Methods
Pooled data from 20 trials were analyzed for patients with T2DM treated with empagliflozin 10 mg (n = 4858), empagliflozin 25 mg (n = 5057), or placebo (n = 4904). The dataset comprised 15 randomized phase I–III trials, an extension trial and dose escalation studies. Adverse events (AEs) were assessed descriptively in participants who took ≥ 1 dose of study drug. AE incidence rates per 100 patient-years were calculated to adjust for differences in drug exposure between trials.
Results
Total exposure was 16,480 and 7857 patient-years in the pooled empagliflozin 10/25 mg and placebo groups, respectively. The incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs was similar across groups. The frequency of serious AEs requiring hospitalization was 18.6% for the empagliflozin 10/25 mg group and 21.3% for the placebo group. The empagliflozin 10/25 mg group was not associated with a higher rate of confirmed hypoglycemia versus placebo, except in patients co-administered insulin and/or a sulfonylurea (31.5% vs. 30.2%, respectively). The incidence of events consistent with urinary tract infections (UTI) was also similar for the empagliflozin 10/25 mg group versus placebo (9.27 vs. 9.70/100 patient-years, respectively). History of UTI was identified as a risk factor for UTI during treatment. Events consistent with genital infections occurred more frequently with empagliflozin 10/25 mg than placebo (3.54 vs. 0.95/100 patient-years, respectively). The frequency of AEs consistent with volume depletion was similar across groups, but higher with empagliflozin 10/25 mg than placebo in patients aged 75 to < 85 years and those on loop diuretics at baseline.
Conclusion
This comprehensive analysis confirms that both empagliflozin 10 mg and 25 mg are well tolerated in patients with T2DM, reinforcing the established clinical safety profile of empagliflozin.
Empagliflozin is a potent sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus (T2DM), including reduction of cardiovascular (CV) mortality in patients with T2DM and CV disease.
The clinical efficacy and safety profile of empagliflozin in T2DM has been well documented; however, new safety signals of increased lower limb amputations and fractures reported for another SGLT2 inhibitor have prompted a review of the risks associated with this drug class.
This study examined the safety and tolerability of empagliflozin in patients with T2DM using data pooled from 20 placebo-controlled clinical trials based on over 16,480 patient-years’ exposure to empagliflozin.
What was learned from the study?
This updated pooled analysis confirmed that both empagliflozin 10 mg and 25 mg are well tolerated in patients with T2DM.
These results reinforce the findings of a favorable benefit–risk profile for empagliflozin from previous clinical trials in patients with T2DM, including trials establishing the effects of empagliflozin on CV and all-cause mortality.
Introduction
Empagliflozin, a potent and selective sodium-glucose co-transporter-2 (SGLT2) inhibitor, is indicated for the treatment of type 2 diabetes mellitus (T2DM) including reduction of cardiovascular (CV) mortality in patients with T2DM and CV disease. By blocking sodium-glucose co-transporters on proximal tubules, empagliflozin induces urinary glucose and sodium excretion which contribute to osmotic diuresis and reductions in plasma volume load [1‐3]. The effects of SGLT2 inhibition on salt, water, and energy metabolism are thought to underlie the CV, renal, and metabolic benefits demonstrated by this drug class [4, 5]. Importantly, as this mechanism of action is independent of insulin modulation by β-cells, SGLT2 inhibitors are associated with a low risk of hypoglycemia [6].
Anzeige
The clinical efficacy and safety profile of empagliflozin in T2DM has been well documented. Treatment with empagliflozin at daily doses of 10 or 25 mg, either as monotherapy or add-on therapy, has been demonstrated to improve glycemic control and to result in reductions in body weight and blood pressure, and was well tolerated in placebo-controlled phase III trials in patients with T2DM [7‐14]. Moreover, in the EMPA-REG OUTCOME® trial, empagliflozin, when given in addition to standard of care and compared with placebo, significantly reduced the risk of CV death by 38%, hospitalization for heart failure by 35%, improved clinically relevant kidney outcomes, and slowed the progression of kidney function decline in patients with T2DM and established CV disease [15, 16]. In the CANagliflozin cardioVascular Assessment Study (CANVAS), the SGLT2 inhibitor canagliflozin has also been shown to lower the risk of CV events in patients with T2DM and elevated risk of CV disease versus placebo [17]. However, a new and important safety signal was reported in the trial: there was a twofold increased risk of lower limb amputations (LLAs; primarily of the toe or metatarsal) in patients in the canagliflozin-treated group, versus placebo {hazard ratio (HR) 1.97 [95% confidence interval (CI) 1.41, 2.75]} [17]. The CANVAS program also reported an increased risk of all fractures with canagliflozin versus placebo [HR 1.26 (95% CI 1.04, 1.52)] [17]. Such new findings have prompted a review of the risks of LLAs and fractures associated with other SGLT2 inhibitors, including empagliflozin and dapagliflozin. For example, in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE–TIMI 58) and Dapagliflozin And Prevention of Adverse–outcomes in Heart Failure (DAPA-HF) trials, dapagliflozin showed no increased risk of either LLAs or fractures versus placebo [18, 19].
A comprehensive analysis of pooled safety profile data for empagliflozin, published in 2016 and derived from clinical trials of more than 9000 patient-years’ exposure to the drug, demonstrated that empagliflozin treatment was well tolerated and not associated with an increased risk of hypoglycemia compared with placebo, except in patients on background treatment with a sulfonylurea (SU) and/or insulin [20]. Furthermore, genital infection was reported to occur in a higher percentage of patients treated with empagliflozin versus placebo [20], which was consistent with findings from previous trials. An update of this pooled analysis, published in 2017, involved in excess of 15,000 patient-years’ exposure, and continued to support the favorable benefit–risk profile of empagliflozin in patients with T2DM [21]. However, a weakness of this larger analysis was that one of its component trials (the EMPA-REG OUTCOME® trial) contributed to over 55% (n = 7020) of the empagliflozin- or placebo-treated patients to the overall analysis population (n = 12,620) [21].
We report here the findings from an additional update on the pooled safety analysis of empagliflozin. This new analysis aims to further describe the safety and tolerability of empagliflozin based on 16,480 patient-years’ exposure to empagliflozin 10 mg or 25 mg in randomized, controlled phase I–III trials.
Methods
Patients
In this updated analysis, data were pooled from 20 trials (Table 1). This included the earlier dataset from 14 trials of 8 days’ to 78 weeks’ duration [7‐14, 22‐27], the 52-week extension trial to the phase III trials of empagliflozin as monotherapy, or as add-on to metformin, metformin plus an SU, and pioglitazone with or without metformin [28‐31], and the CV outcomes trial EMPA-REG OUTCOME® [15]. It included all randomized, double-blind, placebo-controlled trials conducted in ambulatory patients with T2DM, including dose escalation trials and one extension trial of 52 weeks with patients enrolled from three main trials [32‐36]). Data were only included for patients treated with empagliflozin (10/25 mg) or placebo who were randomized using either a 1:1 or 1:1:1 schedule.
Table 1
Overview of the clinical trials included in the pooled safety analysis
ClinicalTrials.gov identifier (BI study number)
Short title
Treatment duration
Dose escalationa
NCT00558571 (1245.4)
4 weeks’ treatment in patients with T2DM
28 days
No
NCT00789035 (1245.9)
Dose finder versus placebo as monotherapy
12 weeks
No
NCT00749190 (1245.10)
Dose finder versus placebo as add-on therapy
12 weeks
No
NCT00885118 (1245.15)
Treatment of patients with T2DM in Japan
4 weeks
No
NCT01210001 (1245.19)
Efficacy on background TZD ± metformin
24 weeks
No
NCT01177813 (1245.20)
Efficacy in drug-naïve patients
24 weeks
No
NCT01159600 (metformin) (1245.23)
Efficacy on background metformin
24 weeks
No
NCT01159600 (metformin + SU) (1245.23)
Efficacy on background metformin ± SU
24 weeks
No
NCT01131676 (1245.25)
Safety cardiovascular outcome trial
Mean: 2.8 years
No
NCT02182830 (1245.29)
African American patients with T2DM and hypertension
24 weeks
Yes
NCT01011868 (1245.33)
Efficacy on background basal insulin
78 weeks
No
NCT01947855 (1245.35)
Japanese post-prandial glucose
4 weeks
No
NCT01164501 (1245.36)
Renal safety study
52 weeks
No
NCT01193218 (1245.38)
Japanese dose finder study plus extension
52 weeks
No
NCT01370005 (1245.48)
Efficacy in patients with T2DM and hypertension
12 weeks
No
NCT01306214 (1245.49)
Efficacy on background MDI insulin ± metformin
52 weeks
No
NCT02589639 (1245.107)
Empagliflozin add-on to insulin (Japan)
52 weeks
No
NCT01734785 (1275.9)
Empagliflozin add-on to linagliptin
24 weeks
No
NCT02453555 (1275.19)
Empagliflozin add-on to linagliptin (Japan)
52 weeks
Yes
NCT01649297 (1276.10)
Empagliflozin QD versus BID on background metformin
16 weeks
No
All trials were randomized, double-blind, and placebo-controlled in ambulatory patients with T2DM treated with empagliflozin 10 or 25 mg
BI Boehringer Ingelheim, BID twice daily, MDI multiple daily injections, QD once daily, SU sulfonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione
aIn some trials, the investigators could decide to increase the dose of empagliflozin from 10 to 25 mg in a blinded manner during the trial
Anzeige
The procedures followed in all studies were in accordance with the ethical standards of the responsible institutional and/or national committees on human experimentation, and with the Helsinki Declaration of 1964, as revised in 2013. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All patients provided their written informed consent prior to participation.
Assessments and Data Analyses
Safety and tolerability were assessed as for the earlier analysis [21], on the basis of investigator-reported adverse events (AEs) that were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1 preferred terms. The safety topics of interest were analyzed using MedDRA version 21.0 preferred terms. A severe AE was any AE adjudged by the investigator to be either incapacitating, causing inability to work, or to perform usual activities. A serious AE was any AE that resulted in death, was immediately life-threatening, resulted in persistent or marked disability/incapacity, required or prolonged patient hospitalization, was a congenital anomaly/birth defect, or was deemed serious for any other reason.
Similar to the previous analysis [21], safety topics of interest included events consistent with hypoglycemia (confirmed hypoglycemia was defined as a plasma glucose level of ≤ 3.9 mmol/l and/or requiring assistance), urinary tract infections, genital infections, volume depletion, diabetic ketoacidosis, urinary tract carcinogenicity, hepatic injury, bone fractures, acute pancreatitis, amputations, and decreased renal function. As LLAs were not systematically reported as separate AEs, the retrieval of these cases involved medical review of the narratives and concomitant therapy data. The present analysis also includes assessments of complicated urinary tract infections (UTIs) and complicated genital infections.
Analyses of AEs were descriptive and based on patients who received at least one dose of the study drug. Exposure-adjusted incidence rates were calculated per 100 patient-years as 100 × n/T where n was the number of patients with the event and T was the total number of patient-years at risk of the event. Patient-years at risk was defined for patients with an event as the time from first dose to the onset of a first event, or for patients without an event, as the time from first dose to the last dose plus 7 days. For LLAs, an intent-to-treat analysis was performed based on cases reported from the first intake of study drug up to trial termination in patients treated with at least one dose of the study drug. Additionally, a time-to-first-event analysis was performed.
The primary analysis was of placebo compared with the pooled empagliflozin 10/25 mg population, as the safety and tolerability of the two empagliflozin doses were shown to be similar in previous analyses [20, 21]. Data from the individual empagliflozin 10 mg and 25 mg groups are also presented in the tables and figure, but exclude the dose-escalation trials.
Results
Patient Disposition, Exposure and Baseline Characteristics
The analysis set included 10,177 patients treated with empagliflozin 10/25 mg and 4904 treated with placebo. Compared with the earlier pooled safety analysis of empagliflozin [21], the current dataset represents an approximate 20% increase in the number of patients analyzed overall (12,620 patients vs. 15,081 patients, respectively). In addition, the EMPA-REG OUTCOME® trial accounted for less than 50% of patients in the current analysis compared with earlier pooled safety analysis [21] (46.5% vs. 55.6%, respectively). However, patients aged ≥ 85 years old (0.2% of overall population) and those with an estimated glomerular filtration rate (eGFR) of < 30 ml/min/1.73 m2 (0.8% of the overall population), were under-represented in the present sample, similar to the earlier analysis [21]. The total study drug exposure was 16,480 and 7857 patient-years in the empagliflozin 10/25 mg and placebo groups, respectively. Patient baseline demographics and clinical characteristics were well balanced across the treatment groups. These are summarized in Table 2.
Table 2
Demographics and baseline characteristics
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
Male, n (%)
3119 (63.6)
3094 (63.7)
3249 (64.2)
6529 (64.2)
Age, years
60.5 (9.8)
60.3 (9.7)
60.4 (9.8)
60.3 (9.7)
Age groups, years (%)
< 65
3197 (65.2)
3168 (65.2)
3293 (65.1)
6639 (65.2)
65 to < 75
1377 (28.1)
1390 (28.6)
1426 (28.2)
2887 (28.4)
75 to < 85
318 (6.5)
290 (6.0)
327 (6.5)
630 (6.2)
≥ 85
12 (0.2)
10 (0.2)
11 (0.2)
21 (0.2)
Race, n (%)
White
3044 (62.1)
3256 (67.0)
3346 (66.2)
6602 (64.9)
Asian
1347 (27.5)
1252 (25.8)
1349 (26.7)
2601 (25.6)
Black/African–American
279 (5.7)
213 (4.4)
219 (4.3)
512 (5.0)
Othera
51 (1.0)
50 (1.0)
51 (1.0)
101 (1.0)
Missing
183 (3.7)
87 (1.8)
92 (1.8)
361 (3.5)
Region, n (%)
Europe
1821 (37.1)
1939 (39.9)
2013 (39.8)
3952 (38.8)
North America
1057 (21.6)
1056 (21.7)
1083 (21.4)
2219 (21.8)
Latin America
474 (9.7)
503 (10.4)
505 (10.0)
1008 (9.9)
Africa/Middle East
132 (2.7)
129 (2.7)
141 (2.8)
270 (2.7)
Asia
1420 (29.0)
1231 (25.3)
1315 (26.0)
2728 (26.8)
Time since diabetes diagnosis, years, n (%)
≤ 1
259 (5.3)
295 (6.1)
308 (6.1)
616 (6.1)
> 1 to ≤ 5
1077 (22.0)
1048 (21.6)
1100 (21.8)
2216 (21.8)
> 5
3553 (72.5)
3500 (72.0)
3633 (71.8)
7314 (71.9)
Missing
15 (0.3)
15 (0.3)
16 (0.3)
31 (0.3)
BMI, kg/m2b
30.4 (5.5)
30.5 (5.5)
30.5 (5.5)
30.5 (5.6)
eGFR, ml/min/1.73 m2, n (%)c
≥ 90
1933 (39.4)
1998 (41.1)
2041 (40.4)
4177 (41.0)
≥ 60 to < 90
2123 (43.3)
2203 (45.3)
2155 (42.6)
4477 (44.0)
≥ 45 to < 60
519 (10.6)
464 (9.6)
535 (10.6)
1003 (9.9)
≥ 30 to < 45
277 (5.6)
182 (3.7)
262 (5.2)
445 (4.4)
< 30
52 (1.1)
10 (0.2)
61 (1.2)
71 (0.7)
Missing
0
1 (< 0.1)
3 (0.1)
4 (< 0.1)
Data are mean (SD) unless otherwise indicated
BMI body mass index, eGFR estimated glomerular filtration rate, EMPA empagliflozin, SD standard deviation
bPlacebo, n = 4883; EMPA 10 mg, n = 4838; EMPA 25 mg, n = 5038; EMPA 10/25 mg, n = 10,138
cPlacebo, n = 4904; EMPA 10 mg, n = 4857; EMPA 25 mg, n = 5054; EMPA 10/25 mg, n = 10,173
General Safety
The overall pattern of AEs observed in the earlier pooled safety analysis [21] was also seen in this updated analysis, with incidences of severe AEs, serious AEs, fatal AEs and AEs leading to treatment discontinuation being similar between the empagliflozin and placebo groups (Table 3). The percentage of patients with a serious AE requiring hospitalization was similar for the empagliflozin and placebo groups (empagliflozin 10/25 mg: 18.6%; placebo: 21.3%) (Table 4). The most common serious AEs requiring hospitalization (based on MedDRA terms) were cardiac disorders (empagliflozin 10/25 mg: 5.7%; placebo: 7.1%), infections and infestations (empagliflozin 10/25 mg: 3.8%; placebo: 4.6%), and nervous system disorders (empagliflozin 10/25 mg: 2.8%; placebo: 3.1%) (Table 5). In contrast, AEs that were deemed by the study investigator to be drug-related were more common in patients treated with empagliflozin compared with the placebo group (empagliflozin 10/25 mg: 25.3%; placebo: 21.0%) (Table 4).
Table 3
Incidence of adverse events
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
≥ 1 AE
197.62
170.01
168.59
168.89
≥ 1 drug-related AEa
15.45
19.57
19.38
19.54
≥ 1 AE leading to discontinuation
7.40
6.57
6.38
6.43
≥ 1 severe AEb
10.43
8.80
9.51
9.04
≥ 1 serious AEc
18.61
15.29
16.07
15.52
Fatal
1.57
1.24
1.01
1.12
Data are the rate/100 patient-years. A patient may be counted in more than one seriousness criterion. MedDRA version used for reporting: 20.1
AE adverse event, EMPA empagliflozin, MedDRA Medical Dictionary for Regulatory Activities
aInvestigator-defined
bAn AE that is incapacitating or causing inability to work or perform usual activities
cAn AE that results in death, is immediately life-threatening, results in persistent or significant disability/incapacity, requires or prolongs patient hospitalization, is a congenital anomaly/birth defect, or is deemed serious for any other reason
Table 4
Frequency of adverse events
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
≥ 1 AE
3942 (80.4)
3740 (77.0)
3896 (77.0)
7805 (76.7)
≥ 1 drug-related AEa
1028 (21.0)
1247 (25.7)
1279 (25.3)
2571 (25.3)
≥ 1 AE leading to discontinuation
565 (11.5)
514 (10.6)
512 (10.1)
1033 (10.2)
≥ 1 severe AEb
747 (15.2)
651 (13.4)
718 (14.2)
1371 (13.5)
≥ 1 serious AEc
1204 (24.6)
1046 (21.5)
1104 (21.8)
2161 (21.2)
Fatal
125 (2.5)
101 (2.1)
84 (1.7)
186 (1.8)
Immediately life-threatening
53 (1.1)
54 (1.1)
64 (1.3)
118 (1.2)
Disability/incapacitation
29 (0.6)
20 (0.4)
27 (0.5)
47 (0.5)
Requiring hospitalization
1044 (21.3)
898 (18.5)
986 (19.5)
1891 (18.6)
Prolonged hospitalization
79 (1.6)
57 (1.2)
76 (1.5)
133 (1.3)
Congenital anomaly
0
0
0
0
Other
193 (3.9)
170 (3.5)
175 (3.5)
348 (3.4)
Data are n (%). A patient may be counted in more than one seriousness criterion. MedDRA version used for reporting: 20.1
AE adverse event, EMPA empagliflozin, MedDRA Medical Dictionary for Regulatory Activities
aInvestigator-defined
bAn AE that is incapacitating or causing inability to work or perform usual activities
cAn AE that results in death, is immediately life-threatening, results in persistent or significant disability/incapacity, requires or prolongs patient hospitalization, is a congenital anomaly/birth defect, or is deemed serious for any other reason
Table 5
Frequency of patients with serious adverse events requiring hospitalization
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
Number of patients
1044 (21.3)
898 (18.5)
986 (19.5)
1891 (18.6)
SOC
Infections and infestations
225 (4.6)
187 (3.8)
200 (4.0)
387 (3.8)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
45 (0.9)
65 (1.3)
75 (1.5)
142 (1.4)
Blood and lymphatic system disorders
18 (0.4)
16 (0.3)
14 (0.3)
30 (0.3)
Immune system disorders
4 (0.1)
3 (0.1)
4 (0.1)
7 (0.1)
Endocrine disorders
3 (0.1)
3 (0.1)
8 (0.2)
11 (0.1)
Metabolism and nutrition disorders
66 (1.3)
42 (0.9)
40 (0.8)
82 (0.8)
Psychiatric disorders
19 (0.4)
11 (0.2)
7 (0.1)
18 (0.2)
Nervous system disorders
152 (3.1)
136 (2.8)
153 (3.0)
289 (2.8)
Eye disorders
26 (0.5)
29 (0.6)
22 (0.4)
51 (0.5)
Ear and labyrinth disorders
17 (0.3)
7 (0.1)
16 (0.3)
23 (0.2)
Cardiac disorders
347 (7.1)
282 (5.8)
296 (5.9)
580 (5.7)
Vascular disorders
115 (2.3)
74 (1.5)
109 (2.2)
183 (1.8)
Respiratory, thoracic and mediastinal disorders
69 (1.4)
43 (0.9)
52 (1.0)
95 (0.9)
Gastrointestinal disorders
93 (1.9)
94 (1.9)
93 (1.8)
187 (1.8)
Hepatobiliary disorders
25 (0.5)
28 (0.6)
30 (0.6)
59 (0.6)
Skin and subcutaneous tissue disorders
28 (0.6)
20 (0.4)
34 (0.7)
54 (0.5)
Musculoskeletal and connective tissue disorders
98 (2.0)
79 (1.6)
81 (1.6)
160 (1.6)
Renal and urinary disorders
69 (1.4)
43 (0.9)
41 (0.8)
84 (0.8)
Pregnancy, puerperium and perinatal conditions
0
0
1 (< 0.1)
1 (< 0.1)
Reproductive system and breast disorders
10 (0.2)
18 (0.4)
19 (0.4)
37 (0.4)
Congenital, familial and genetic disorders
6 (0.1)
4 (0.1)
2 (< 0.1)
6 (0.1)
General disorders and administration site conditions
75 (1.5)
58 (1.2)
62 (1.2)
121 (1.2)
Investigations
18 (0.4)
8 (0.2)
15 (0.3)
23 (0.2)
Injury, poisoning and procedural complications
83 (1.7)
69 (1.4)
80 (1.6)
151 (1.5)
Surgical and medical procedures
15 (0.3)
14 (0.3)
16 (0.3)
30 (0.3)
Social circumstances
0
1 (< 0.1)
0
1 (< 0.1)
Product issues
4 (0.1)
0
2 (< 0.1)
2 (< 0.1)
Data are n (%). A patient could have more than one event. MedDRA version used for reporting: 20.1
EMPA empagliflozin, MedDRA Medical Dictionary for Regulatory Activities, SOC System Organ Class
Safety Topics of Interest
Hypoglycemia
The frequency and incidence rate of hypoglycemic AEs were similar for empagliflozin and placebo in all-comers (empagliflozin 10/25 mg: 20.3%, 15.69 events per 100 patient-years; placebo: 21.3%, 16.32 events per 100 patient-years) (Table 6). However, a higher percentage of patients that used insulin and/or an SU at baseline in the empagliflozin 10/25 mg than placebo groups reported confirmed hypoglycemic AEs (empagliflozin 10/25 mg: 31.5%, 20.88 events per 100 patient-years; placebo: 30.2%, 20.36 per 100 patient-years) (Table 6).
Table 6
Frequency and incidence rate of important identified risks
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
n (%) or n/N (%)
Rate/100 pt-yrs
n (%) or n/N (%)
Rate/100 pt-yrs
n (%) or n/N (%)
Rate/100 pt-yrs
n (%) or n/N (%)
Rate/100 pt-yrs
UTIs (BIcMQ)
691 (14.1)
9.70
684 (14.1)
9.45
675 (13.3)
9.04
1382 (13.6)
9.27
Sex
Male
204/3119 (6.5)
3.97
225/3094 (7.3)
4.33
224/3249 (6.9)
4.11
455/6529 (7.0)
4.21
Female
487/1785 (27.3)
24.50
459/1764 (26.0)
22.43
451/1808 (24.9)
22.35
927/3648 (25.4)
22.55
Age, years
< 65
401/3197 (12.5)
9.00
389/3168 (12.3)
8.58
360/3293 (10.9)
7.71
762/6639 (11.5)
8.16
65 to < 75
220/1377 (16.0)
10.35
216/1390 (15.5)
9.64
243/1426 (17.0)
10.59
466/2887 (16.1)
10.14
75 to < 85
69/318 (21.7)
13.39
79/290 (27.2)
17.38
71/327 (21.7)
14.72
153/630 (24.3)
16.13
≥ 85
1/12 (8.3)
4.61
0/10
–
1/11 (9.1)
4.48
1/21 (4.8)
2.98
Complicated UTIs (BIcMQ)
59 (1.2)
0.75
39 (0.8)
0.48
54 (1.1)
0.65
93 (0.9)
0.56
Genital infections (BIcMQ)
75 (1.5)
0.95
278 (5.7)
3.57
281 (5.6)
3.52
565 (5.6)
3.54
Sex
Male
35/3119 (1.1)
0.66
139/3094 (4.5)
2.62
116/3249 (3.6)
2.07
255/6529 (3.9)
2.30
Female
40/1785 (2.2)
1.58
139/1764 (7.9)
5.61
165/1808 (9.1)
6.98
310/3648 (8.5)
6.33
Age, years
< 65
50/3197 (1.6)
1.03
192/3168 (6.1)
4.01
192/3293 (5.8)
3.93
386/6639 (5.8)
3.93
65 to < 75
21/1377 (1.5)
0.88
69/1390 (5.0)
2.81
71/1426 (5.0)
2.82
144/2887 (5.0)
2.86
75 to < 85
4/318 (1.3)
0.68
17/290
(5.9)
3.21
17/327 (5.2)
3.13
34/630 (5.4)
3.13
≥ 85
0/12
–
0/10
–
1/11 (9.1)
4.35
1/21 (4.8)
2.92
Complicated genital infections (BIcMQ)
24 (0.5)
0.30
29 (0.6)
0.36
26 (0.5)
0.31
55 (0.5)
0.33
Hypoglycemia (narrow SMQ)
1045 (21.3)
16.32
1009 (20.8)
15.79
1053 (20.8)
16.02
2067 (20.3)
15.69
Confirmed hypoglycemic AEs
987 (20.1)
945 (19.5)
1000 (19.8)
1948 (19.1)
Confirmed hypoglycemiaa with baseline use of insulin and/or SU
915 (30.2)
20.36
889 (31.9)
20.92
942 (31.2)
20.84
1,833 (31.5)
20.88
Confirmed hypoglycemia without baseline use of insulin and/or SU
54 (2.9)
2.66
38 (1.8)
1.67
46 (2.3)
2.13
85 (2.0)
1.83
Diabetic ketoacidosis (narrow BIcMQb)
4 (0.1)
0.05
4 (0.1)
0.05
2 (< 0.1)
0.02
6 (0.1)
0.04
Urinary tract carcinogenicityc (BIcMQ)
9 (0.2)
0.11
10 (0.2)
0.12
13 (0.3)
0.16
23 (0.2)
0.14
Onset after 6 months’ treatment
7 (0.2)
0.12
8 (0.2)
0.13
10 (0.3)
0.16
18 (0.3)
0.15
Liver injury (SMQ)
157 (3.2)
2.02
109 (2.2)
1.36
135 (2.7)
1.65
247 (2.4)
1.51
Bone fractures (BIcMQ)
134 (2.7)
1.72
121 (2.5)
1.52
107 (2.1)
1.30
233 (2.3)
1.42
Pancreatitis (SMQ)
11 (0.2)
0.14
8 (0.2)
0.10
7 (0.1)
0.08
15 (0.1)
0.09
Amputation risk (ITT population)
46 (0.9)
0.52
46 (0.9)
0.51
49 (1.0)
0.54
95 (0.9)
0.52
Minor
27 (0.6)
0.30
36 (0.7)
0.40
40 (0.8)
0.44
76 (0.8)
0.41
Major
19 (0.4)
0.21
10 (0.2)
0.11
9 (0.2)
0.10
19 (0.2)
0.10
AE adverse event, BIcMQ Boehringer Ingelheim customized MedDRA query, EMPA empagliflozin, ITT intent-to-treat, MedDRA Medical Dictionary for Regulatory Activities, pt-yrs patient-years, SMQ standardized MedDRA queries, SU sulfonylurea, UTI urinary tract infection
aConfirmed hypoglycemia was defined as plasma glucose ≤ 3.9 mmol/l and/or requiring assistance
bThe lower number of events in the placebo group compared with the previously updated pooled safety analysis [21] is due to a change in definition resulting from a revision in MedDRA mapping between versions (i.e., the lowest level term ‘diabetic ketosis’ was mapped to the preferred term ‘diabetic ketoacidosis’ in version 18.0; however, this is no longer the case in version 21.0)
cBladder and renal malignancies
Urinary Tract Infections
The frequency and incidence of events consistent with UTI was higher among females compared with males in all treatment groups, but was similar when comparing empagliflozin with placebo in both males and females [empagliflozin 10/25 mg: (females) 25.4%, 22.55 events per 100 patient-years, (males) 7.0%, 4.21 events per 100 patient-years; placebo: (females) 27.3%, 24.50 events per 100 patient-years, (males) 6.5%, 3.97 events per 100 patient-years] (Table 6). Excluding patients aged ≥ 85 years, the frequency and incidence of UTI increased with age in all treatment groups, but, again, the frequency and incidence of UTI was similar when comparing empagliflozin with placebo in all age groups (Table 6). The majority of these events were non-serious, mild or moderate in intensity and led to treatment discontinuation in < 1% of treated patients in the empagliflozin 10/25 mg and placebo groups (Table 7). Similar proportions of patients (< 1%) with UTIs that either required or prolonged hospitalization were observed in the empagliflozin 10/25 mg and placebo groups (Table 7). Approximately one-third of patients in both the empagliflozin 10/25 mg and placebo groups with a history of chronic or recurrent UTIs had a UTI during treatment (Table 7). Similar proportions of patients in the empagliflozin 10/25 mg and placebo groups had complicated UTIs (0.9% vs. 1.2%, respectively; Table 7).
Table 7
Frequency and incidence rate for UTIs and genital infections by seriousness, need for hospitalization, treatment discontinuation, history of chronic or recurrent infection, and complicated infection
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
UTIs (BIcMQ)a
Serious UTIs
39 (0.8)
0.49
27 (0.6)
0.33
39 (0.8)
0.47
66 (0.6)
0.40
Requires or prolongs hospitalization
38 (0.8)
0.5
26 (0.5)
0.3
39 (0.8)
0.5
65 (0.6)
0.4
Treatment discontinued
15 (0.3)
0.19
27 (0.6)
0.33
25 (0.5)
0.30
52 (0.5)
0.31
History of chronic or recurrent UTIb
Yes
100/277 (36.1)
32.46
98/280 (35.0)
28.58
102/313 (32.6)
28.41
205/615 (33.5)
28.82
No
573/4267 (13.4)
8.71
559/4221 (13.2)
8.39
550/4402 (12.5)
7.98
1126/8863 (12.7)
8.20
Complicated UTIsc
59 (1.2)
0.75
39 (0.8)
0.48
54 (1.1)
0.65
93 (0.9)
0.56
Genital infections (BIcMQ)d
Serious genital infections
3 (0.1)
0.04
8 (0.2)
0.10
4 (0.1)
0.05
12 (0.1)
0.07
Requires or prolongs hospitalization
3 (0.1)
< 0.1
8 (0.2)
0.1
4 (0.1)
< 0.1
12 (0.1)
0.1
Treatment discontinued
2 (< 0.1)
0.03
26 (0.5)
0.32
21 (0.4)
0.25
47 (0.5)
0.28
History of chronic or recurrent genital infectione
Yes
6/76 (7.9)
5.25
17/76 (22.4)
17.93
22/92 (23.9)
23.47
39/172 (22.7)
20.30
No
66/4468 (1.5)
0.88
243/4425 (5.5)
3.27
249/4623 (5.4)
3.25
498/9306 (5.4)
3.25
Complicated genital infectionsf
24 (0.5)
0.30
29 (0.6)
0.36
26 (0.5)
0.31
55 (0.5)
0.33
Data are n (%) except where indicated
AE adverse event, BIcMQ Boehringer Ingelheim customized MedDRA query, EMPA empagliflozin, MedDRA Medical Dictionary for Regulatory Activities, pt-yrs patient-years, UTI urinary tract infection
aBased on pre-defined MedDRA preferred terms, of which UTI, asymptomatic bacteriuria, and cystitis were the most frequent
bNumber of patients with UTIs/number of treated patients in subgroup (number of patients with UTIs as % of number of treated patients in subgroup)
cAll upper UTIs reported as serious or non-serious AEs and all lower UTIs reported as serious AEs
dBased on pre-defined MedDRA preferred terms, of which balanoposthitis, vulvovaginal mycotic infection, and vulvovaginal candidiasis were the most frequent
eNumber of patients with genital infections/number of treated patients in subgroup (number of patients with genital infections as % of number of treated patients in subgroup)
fEvents related to abscesses of external genital organs, endometritis, adnexitis, prostatitis, orchiepididymitis, pelvic infections, and serious AEs of vulvovaginitis and balanoposthitis
Genital Infections
The frequency and incidence of events consistent with genital infections was higher among females compared with males in all treatment groups, and was higher for empagliflozin than placebo in both males and females [empagliflozin 10/25 mg: (females) 8.5%, 6.33 events per 100 patient-years, (males) 3.9%, 2.30 events per 100 patient-years; placebo: (females) 2.2%, 1.58 events per 100 patient-years, (males) 1.1%, 0.66 events per 100 patient-years], and in all age groups (Table 6). As for UTIs, the majority of genital infections were non-serious, mild or moderate in intensity and led to treatment discontinuation in < 1% of patients in each of the treatment groups (Table 7). In addition, < 1% of patients across treatment groups had genital infections that required or prolonged hospitalization (Table 7). The frequency of events consistent with genital infections was higher in patients with a history of chronic or recurrent genital infections compared with patients without such a history for both empagliflozin 10/25 mg and placebo (empagliflozin 10/25 mg: 22.7% vs. 5.4%; placebo: 7.9% vs. 1.5%, respectively) (Table 7). Moreover, complicated genital infection rates were consistently low and similar across groups (0.5% for both empagliflozin 10/25 mg and placebo) (Table 7).
Volume Depletion
A higher rate of volume depletion was reported in patients with hypotension at baseline versus without, in patients treated with diuretics or loop diuretics at baseline than without, and in patients taking angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blockers (ARBs) or antihypertensive drugs at baseline than without (Table 8). However, the frequency of events consistent with volume depletion was similar between patients treated with empagliflozin 10/25 mg and placebo in these subgroups, except for patients aged 75 to < 85 years (5.9% vs. 5.0%, respectively), and patients treated with loop diuretics at baseline (9.8% vs. 7.4%, respectively), where the frequency was higher for empagliflozin 10/25 mg compared with placebo (Table 8).
Table 8
Frequencies for volume depletion by age, hypotension at baseline, and concomitant drugs at baseline
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
Volume depletiona (BIcMQ)
147 (3.0)
150 (3.1)
169 (3.3)
320 (3.1)
Age (years)
< 65
62/3197 (1.9)
59/3168 (1.9)
73/3293 (2.2)
132/6639 (2.0)
65 to < 75
67/1377 (4.9)
73/1390 (5.3)
75/1426 (5.3)
149/2887 (5.2)
75 to < 85
16/318 (5.0)
18/290 (6.2)
19/327 (5.8)
37/630 (5.9)
≥ 85
2/12 (16.7)
0/10
2/11 (18.2)
2/21 (9.5)
Hypotension at baseline
Yes
17/244 (7.0)
15/254 (5.9)
9/276 (3.3)
24/542 (4.4)
No
130/4602 (2.8)
135/4548 (3.0)
160/4727 (3.4)
296/9525 (3.1)
Use of diuretics at baseline
Yes
83/1660 (5.0)
79/1602 (4.9)
96/1703 (5.6)
175/3349 (5.2)
No
64/3244 (2.0)
71/3256 (2.2)
73/3354 (2.2)
145/6828 (2.1)
Use of loop diuretics at baseline
Yes
36/488 (7.4)
42/415 (10.1)
47/489 (9.6)
89/909 (9.8)
No
111/4416 (2.5)
108/4443 (2.4)
122/4568 (2.7)
231/9268 (2.5)
Use of ACE inhibitor/ARB at baseline
Yes
121/3256 (3.7)
126/3261 (3.9)
142/3360 (4.2)
269/6733 (4.0)
No
26/1648 (1.6)
24/1597 (1.5)
27/1697 (1.6)
51/3444 (1.5)
Use of antihypertensive drugs at baseline
Yes
140/3922 (3.6)
142/3857 (3.7)
158/3986 (4.0)
301/7996 (3.8)
No
7/982 (0.7)
8/1001 (0.8)
11/1071 (1.0)
19/2181 (0.9)
Data are n (%) except where indicated. Percentages are calculated using the total number of patients per treatment as the denominator
ACE angiotensin-converting enzyme, ARB angiotensin-receptor blocker, BIcMQ Boehringer Ingelheim customized MedDRA query, EMPA empagliflozin, MedDRA Medical Dictionary for Regulatory Activities
aBased on pre-defined MedDRA preferred terms, of which hypotension, syncope, and dehydration were the most frequent
Diabetic Ketoacidosis
The frequency and incidence of diabetic ketoacidosis were similar for patients treated with empagliflozin and placebo (empagliflozin 10/25 mg: 0.1%, 0.04 events per 100 patient-years; placebo: 0.1%, 0.05 events per 100 patient-years) (Table 6). Of four patients in the placebo group with diabetic ketoacidosis, none discontinued treatment and symptoms eventually resolved in all patients. Of six patients in the empagliflozin 10/25 mg group who experienced diabetic ketoacidosis, two discontinued treatment and symptoms resolved in five patients (the status of one patient was unknown).
Urinary Tract Carcinogenicity
The frequency and incidence of events consistent with urinary tract carcinogenicity (bladder and renal malignancies) with an onset of at least 6 months from the start of treatment were similar for the empagliflozin 10/25 mg and placebo groups (empagliflozin 10/25 mg: 0.3%, 0.15 events per 100 patient-years; placebo: 0.2%, 0.12 events per 100 patient-years) (Table 6).
Liver Injury
The frequency and incidence of events consistent with hepatic injury were similar for the empagliflozin and placebo groups (empagliflozin 10/25 mg: 2.4%, 1.51 events per 100 patient-years; placebo: 3.2%, 2.02 events per 100 patient-years) (Table 6). Elevations in alanine aminotransferase and/or aspartate aminotransferase ≥ 5 times the upper limit of normal were more frequent with empagliflozin 10/25 mg versus placebo (0.4% vs. 0.2%, respectively) (Table 9).
Table 9
Elevations in liver enzymes and bilirubina
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
ALT and/or AST ≥ 3 × ULN
65 (1.3)
50 (1.0)
45 (0.9)
99 (1.0)
ALT and/or AST ≥ 5 × ULN
11 (0.2)
18 (0.4)
21 (0.4)
40 (0.4)
ALT and/or AST ≥ 3 × ULN with total bilirubin ≥ 2 × ULNb
2 (< 0.1)
5 (0.1)
5 (0.1)
10 (0.1)
Data are n (%) in patients who received at least one dose of study drug
ALT alanine aminotransferase, AST aspartate aminotransferase, EMPA empagliflozin, ULN upper limit of normal
aPatients are presented regardless of baseline elevations
bPatients with ALT and/or AST ≥ 3 × ULN with concomitant or subsequent total bilirubin ≥ 2 × ULN in a 30-day period after ALT and/or AST elevation
Bone Fractures
The frequency and incidence of bone fractures were similar for the empagliflozin 10/25 mg and placebo groups (empagliflozin 10/25 mg: 2.3%, 1.42 events per 100 patient-years; placebo: 2.7%, 1.72 events per 100 patient-years) (Table 6).
Pancreatitis
The frequency and incidence of pancreatitis, including acute pancreatitis, were similar for the empagliflozin 10/25 mg and placebo groups (empagliflozin 10/25 mg: 0.1%, 0.09 events per 100 patient-years; placebo: 0.2%, 0.14 events per 100 patient-years) (Table 6).
Lower Limb Amputation Risk
In the current pooled safety analysis LLAs, including minor (at the ankle or below) and major (above the ankle) amputations, occurred in 95 and 46 patients in the intent-to-treat analysis who were treated with empagliflozin 10/25 mg and placebo, respectively. There was no difference in the overall incidence rate of LLAs between the empagliflozin 10/25 mg and placebo groups (0.52 vs. 0.52 cases per 100 patient-years, respectively) (Table 6). The degree of amputation was less often major in the empagliflozin 10/25 mg group than in the placebo group (0.10 vs. 0.21 cases per 100 patient-years, respectively), and more often minor in the empagliflozin 10/25 mg group than in the placebo group (0.41 vs. 0.30 cases per 100 patient-years, respectively) (Table 6). In addition, analysis of the EMPA-REG OUTCOME® trial, from which the majority of the cases of amputation were reported, showed that the proportion of patients with LLA was similar between the treatment groups, and that empagliflozin was not associated with an increased risk of LLA versus placebo in the trial [21, 37].
Renal Impairment
The frequency and incidence of renal impairment events, including acute kidney injury, were similar for the empagliflozin and placebo groups (empagliflozin 10/25 mg: 2.9%, 1.78 events per 100 patient-years; placebo: 2.4%, 2.18 events per 100 patient-years) (Table 10). In particular, the overall frequency of events across treatment groups, assessed by baseline eGFR range, was similar, including in patients with a reduced eGFR of ≥ 30 to < 45 ml/min/1.73 m2 (empagliflozin 10/25 mg: 12.8%; placebo: 13.4%) and < 30 ml/min/1.73 m2 (empagliflozin 10/25 mg: 12.7%; placebo: 11.5%). Kaplan–Meier estimates of time to first renal impairment event for patients treated with empagliflozin compared with placebo are shown in Fig. 1.
Table 10
Frequency and incidence rate of user-defined renal impairment events
Placebo (n = 4904)
EMPA 10 mg (n = 4858)
EMPA 25 mg (n = 5057)
EMPA 10/25 mg (n = 10,177)
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
n (%)
Rate/100 pt-yrs
Renal impairment
169 (3.4)
2.18
139 (2.9)
1.75
152 (3.0)
1.86
291 (2.9)
1.78
Acute kidney injurya
44 (0.9)
0.56
29 (0.6)
0.36
28 (0.6)
0.34
57 (0.6)
0.34
Renal impairment by baseline eGFR (CKD-EPI), ml/min/1.73 m2, n (%)
Kaplan–Meier estimates of time to onset of first event suggestive of renal impairment
×
Discussion
In the EMPA-REG OUTCOME® trial in patients with T2DM and established CV disease, empagliflozin reduced the risk of CV death by 38% compared with placebo [15]. Patients treated with empagliflozin also experienced a 32% reduction in the risk of all-cause mortality, a 35% reduction in the risk of hospitalization for heart failure, and a 39% reduction in the risk of incident or worsening nephropathy [15, 16, 38]. In addition, empagliflozin has been estimated to increase life expectancy by an average of 1–4.5 years (depending on age), compared with placebo [39].
Anzeige
This analysis of pooled safety data for empagliflozin was of an expanded dataset previously used to investigate the safety and tolerability of empagliflozin in patients with T2DM [21]. Whereas the earlier analysis was based on more than 15,000 patient-years’ exposure to empagliflozin [21], the present expanded dataset was based on more than 16,480 patient-years’ exposure.
Following this earlier analysis [21], the present analysis showed a consistent AE profile and further continued to show that empagliflozin has a good safety profile and is well tolerated in patients with T2DM. In addition, the risk of hypoglycemia was similar for empagliflozin compared with placebo, except when co-administered with insulin and/or an SU.
Due to their mechanism of action, SGLT2 inhibitors cause transient increases in urine volume [1, 2], leading to acknowledgement of its potential for volume depletion and hypotension, particularly in the elderly population. The present analyses showed that the risk of volume depletion for empagliflozin compared with placebo was numerically increased in patients aged 75 to < 85 years, and in patients with concomitant use of loop diuretics, but not in patients with concomitant use of other diuretics, ACE inhibitors/ARBs, or other antihypertensive drugs.
Similarly, UTIs and genital infections are both identified risks associated with SGLT2 inhibitor use, with increases in urinary glucose concentration a potential exacerbating factor [40]. The present data continue to support previous findings that there is no empagliflozin-specific increased risk of UTIs when compared with placebo. Furthermore, the notion that increased urinary glucose concentration and excretion might predispose to UTIs may be counterbalanced with the hypothesis that increased urinary flow due to osmotic diuresis may reduce or balance the potential impact of increased urinary glucose concentration. The risk of genital infection was elevated for empagliflozin compared with placebo, but excess events associated with empagliflozin were predominantly mild or moderate in intensity and seldom led to treatment discontinuation. There was no increased risk of complicated UTIs or complicated genital infections associated with empagliflozin compared with placebo.
Anzeige
The risk of diabetic ketoacidosis, a serious complication associated with diabetes that arises when the body produces high levels of ketones, may be increased by the use of SGLT2 inhibitors [41]. No imbalance in diabetic ketoacidosis has been reported in clinical trials [15, 17, 18], and there was a similar frequency in the present data for patients treated with empagliflozin compared with placebo. Despite this, in 2015, the US Food and Drug Administration issued a safety announcement of the potential for an increased risk of diabetic ketoacidosis with SGLT2 inhibitor treatment [42]. This was the result of post-marketing reports, coupled with a potential mechanism of action of SGLT2 inhibitors involving the metabolic shift towards lipid utilization, leading to increased ketone body production, particularly during prolonged fasting [43]. As a result, the labels for all SGLT2 inhibitors were updated with a warning of this complication [44].
Recently, based on a number of post-marketing reports, the labels for SGLT2 inhibitors were also updated with an adverse reaction of Fournier’s gangrene, which is a rare but serious urological condition, characterized by a progressive necrotizing infection that affects the external genitalia or the perineum [45]. No cases of Fournier’s gangrene have been reported in clinical trials with empagliflozin. Six cases of Fournier’s gangrene were recorded in the DECLARE-TIMI 58 trial, one in the dapagliflozin group and five in the placebo group [18].
Previously, a concern of bladder cancer relating to SGLT2 inhibitor use was raised, particularly in relation to dapagliflozin [46, 47]. However, this risk was not confirmed in the DECLARE–TIMI 58 trial, a large placebo-controlled CV outcome trial [18]. There was also no increased risk of urinary tract cancer in the present analysis. In addition, an analysis of patients with at least 6 months’ drug exposure in EMPA-REG OUTCOME® was undertaken to assess the risk of bladder cancer [48]. The incidence, with an onset after 6 months’ cumulative exposure to the study drug, was reported in 10/4406 patients (0.2%) in the empagliflozin 10/25 mg group and 4/2187 patients (0.2%) in the placebo group. The authors concluded that, based on the totality of the data, no imbalance in bladder cancer cases between empagliflozin and placebo was observed in EMPA-REG OUTCOME® [48].
The CANVAS program reported an increased risk of fractures and LLAs with canagliflozin use, with LLAs consistent for minor and major amputations [17]. In 2017, regulators reviewed available data for possible associations between SGLT2 inhibitors and LLAs. They concluded that canagliflozin may increase the risk of LLA, and the US Food and Drug Administration issued a boxed warning to the canagliflozin label describing the increased risk of leg and foot amputations [49]. In the current analysis, there was no evidence of an association between empagliflozin use and LLAs. The overall frequency of amputations was the same for empagliflozin compared with placebo. In addition, the EMPA-REG OUTCOME® trial found that the proportion of patients with an LLA was similar between the empagliflozin and placebo groups [21]. Similarly, the DECLARE-TIMI 58 trial of over 17,000 patients found no increased risk of amputations between dapagliflozin and placebo [18]. A meta-analysis of the CANVAS program, EMPA-REG OUTCOME® and DECLARE-TIMI 58 trials showed that the increased risk of amputations and fractures in the CANVAS program contributed moderate to high percentages of the total variation across the three trials that was due to heterogeneity (I2 = 79.1% for amputations and I2 = 42.1% for fractures) [5]. In the recent CREDENCE study in 4401 patients with diabetes and albuminuric chronic kidney disease receiving canagliflozin or placebo on top of standard of care, there was no significant difference in the rates of amputation reported (HR 1.11 [95% CI 0.79, 1.56]) [50].
Anzeige
Other potential risks associated with SGLT2 inhibitor use, including liver injury, bone fracture, and pancreatitis, all occurred at a similar frequency for patients treated with empagliflozin and placebo. The events related to renal impairment for patients with reduced eGFR were similar for patients treated with empagliflozin compared with placebo.
Strengths of this analysis include the large sample size and patient exposure. Weaknesses include that the studies were of varying durations and that differences between groups were not compared using modeled analyses.
Conclusion
This pooled analysis, based on over 16,480 patient-years’ exposure to empagliflozin in placebo-controlled trials, confirms previous knowledge of the tolerability of empagliflozin 10 and 25 mg in patients with T2DM. Empagliflozin was not associated with a higher rate of confirmed hypoglycemic events compared with placebo, except when co-administered with insulin and/or an SU. In both the placebo and empagliflozin groups, there was a higher rate of volume depletion in patients with baseline hypotension versus normotension, and in patients taking diuretics, loop diuretics, ACE inhibitors/ARBs, or anti-hypertensive drugs, compared with patients not taking these medications. The frequency and incidence rates of events consistent with volume depletion were similar between patients treated with empagliflozin and placebo, except for patients aged 75 to < 85, and for patients treated with loop diuretics at baseline, where the frequency was higher for empagliflozin compared with placebo. Genital infections, but not UTIs, were more frequent in patients treated with empagliflozin than placebo. There was no difference in the incidence of LLA in the pooled empagliflozin group versus placebo. The incidences of bone fractures, urinary tract carcinogenicity, renal impairment, liver injury, pancreatitis, and diabetic ketoacidosis were not increased with empagliflozin compared with placebo in clinical trials. Further information on the safety and tolerability profile of empagliflozin will be provided by post-marketing surveillance and ongoing clinical trials. Overall, this analysis shows that empagliflozin is a well-tolerated SGLT2 inhibitor that reduces all-cause mortality in patients with T2DM and established CV disease while displaying a favorable benefit-risk profile.
Acknowledgements
The authors thank the participants of the studies that provided data for this analysis.
Funding
The studies were funded by Boehringer Ingelheim or the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance. The article Rapid Service Fee and Open Access Fee were funded by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.
Medical Writing and/or Editorial Assistance
Medical writing assistance was supported financially by Boehringer Ingelheim and provided by Charlie Bellinger and Céline Tevlin of Elevate Scientific Solutions, Horsham, UK.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Disclosures
Ona Kinduryte Schorling is employed by Boehringer Ingelheim. Douglas Clark is employed by Boehringer Ingelheim. Isabella Zwiener is employed by Boehringer Ingelheim. Stefan Kaspers is employed by Boehringer Ingelheim. Jisoo Lee is employed by Boehringer Ingelheim. Hristo Iliev is employed by Boehringer Ingelheim.
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All participants gave signed and dated informed consent prior to inclusion.
Data Availability
The sponsor of the clinical trials (Boehringer Ingelheim) is committed to responsible sharing of clinical study reports, related clinical documents, and patient-level clinical study data. The datasets analyzed during the current study are available in the Boehringer Ingelheim repository (https://trials.boehringer-ingelheim.com/). Researchers are invited to submit inquiries via the Boehringer Ingelheim website.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
